Apanna: Creating an integrated platform for mind-body-spirit solopreneurs

Apanna: Creating an integrated platform for mind-body-spirit solopreneurs

By Jordana Starr | September 25, 2017 (Innovate413): Amherst Mindfulness owner Michele Miller offers educational courses and workshops relating to mindfulness—a form of meditation that involves awareness of one’s present thoughts, feelings, body, and environment—at the Yoga Center in the heart of downtown Amherst. When she first started teaching, she was frustrated with the lack of a single platform that could allow her to market her business, register students, accept payments, and connect virtually with her students. As Miller recognized a need for an integrated platform...

Intarcia Strengthens Board of Directors for Next Stage of Growth

Intarcia Strengthens Board of Directors for Next Stage of Growth

BOSTON – September 20, 2017 – Intarcia Therapeutics, Inc. today announced the appointment of four new members to its board of directors. Dr. Patrick Conway, Jim Rosenthal, Dr. Jay Skyler and the Honorable Bob Kerrey will be joining the board. Each of these industry leaders and experts in their fields are expected to add significant and sustained value for Intarcia as it continues to develop and advance life-changing therapeutic options to address treatment and prevention outcomes in some of the most devastating and costly chronic diseases around the world. They will also provide...

New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetes

BOSTON – September 15, 2017 – Intarcia Therapeutics, Inc., announced top-line results from FREEDOM-3S which assessed the tolerability and optimal dosing regimen of two different ITCA 650 (exenatide in osmotic mini-pump) dosing approaches when switching patients with type 2 diabetes from stable therapy with liraglutide to ITCA 650. The trial demonstrated that patients receiving 1.2 or 1.8 mg of an injectable liraglutide treatment can be switched directly to the full dose six-month ITCA 650 60 mcg/day osmotic mini-pumps. Patients tolerated the switch to ITCA 650 very well. There was also no statistically significant difference in safety or tolerability when switching directly to the full dose six-month 60 mcg/day mini-pumps versus first switching to the..

Fixing the Stock Market’s ‘Clogged Toilet’ Starts in Delaware

Fixing the Stock Market’s ‘Clogged Toilet’ Starts in Delaware

Patrick Byrne may finally get his vindication. The chief executive officer of Overstock.com Inc. has fought for a dozen years against a market abuse called naked short selling, where investors bet a stock will drop without first taking the required step of borrowing shares. He says it was used back in 2005 to drive down his company’s stock, an episode that spurred a Securities and Exchange Commission probe and set Byrne on a crusade to improve accountability in the system that underlies U.S. stock ownership. Finally an answer is near, thanks to Delaware. Last month, the home state...

Medici Ventures Announces Strategic Investment in Symbiont

Medici Ventures Announces Strategic Investment in Symbiont

Medici Ventures and Symbiont today announced the completion of a strategic investment in Symbiont by Medici Ventures, a major investor in blockchain technology. As part of the new relationship, the two companies will collaborate on strategic projects involving both Medici Ventures and its parent company, Overstock.com.

Safer Sex Without Pills or Condoms?

Safer Sex Without Pills or Condoms?

Earlier this year the Bill & Melinda Gates Foundation teamed up with Intarcia Therapeutics to invest $140 million in a yearly pre-exposure prophylaxis to prevent the transmission of HIV. Intarcia is at a critical phase in developing the new technology, which could reach far beyond HIV prevention. The company hopes to expand...

Symbiont Announces Strategic Partnership and Investment from Hundsun Technologies

Symbiont Announces Strategic Partnership and Investment from Hundsun Technologies

Symbiont, the market-leading smart contracts platform for institutional applications of distributed ledger technology, today announced a strategic partnership with Chinese software giant Hundsun Technologies Inc, which includes an investment by a division of Hundsun in Symbiont’s Series A-1 round. The investment is Hundsun’s first in both the United States and in distributed ledger technology. Symbiont’s board of directors...

How a Tiny, Implantable Drug Could Prevent HIV

How a Tiny, Implantable Drug Could Prevent HIV

In the future, it may be possible to prevent HIV through the help of a miniature pump that’s been implanted underneath one’s skin. That’s the promise of the pharmaceutical company Intarcia Therapeutics, whose chairman and president Kurt Graves spoke at Fortune’s Brainstorm Health conference Tuesday in San Diego.  Intarcia is currently developing an HIV-preventing drug and treatment technology that Graves hopes could eventually solve a big problem facing the health care industry and the treatment of chronic diseases

The Long Game In Life Sciences: $181B Fund Baillie Gifford Invests Big In Private Companies

The Long Game In Life Sciences: $181B Fund Baillie Gifford Invests Big In Private Companies

Traditional life sciences investors have made lots and lots of money from recent multibillion-dollar exits like Receptos, Alios and Acerta. But lately I’ve noticed a different life sciences investing strategy, one closer to the way social/mobile/software investors invest. By paying higher entry prices for later mega-rounds in ambitious life sciences companies, including both therapeutics and non-therapeutics companies, these deep-pocketed investors hope to reproduce their earlier successes investing in the likes of Amazon and Tesla. Their capital, which comes without the usual board seats and tight monitoring, is deeply welcome, because it allows these companies (similar to consumer companies like Airbnb and Uber) to stay under the radar much longer than...

Intarcia and Calibr Partner for Combined Product to Fight Diabetes and Obesity

Intarcia and Calibr Partner for Combined Product to Fight Diabetes and Obesity

Intarcia Therapeutics, Inc. and the California Institute for Biomedical Research (Calibr) today announced a strategic research collaboration focused on the development of a novel peptide therapeutic leveraging Calibr’s Stapled-Peptide Platform Technology. Intarcia plans to develop and administer this novel therapy in combination with Exenatide (a GLP-1 receptor agonist and active agent in Intarcia’s ITCA 650 product), by leveraging its proprietary Medici Drug Delivery System™. Under the terms of the agreement, Calibr will...

Delaware's 2017 Resolution: Symbioint to Make Blockchain a Reality

If 2016 marked the year that Delaware became the first US state to implement block-chain technology, 2017 will mark another first. This year, we expect companies will be able to file documents on our distributed ledger, in addition to current filing procedures. But while we're just one state in one country, this move is no small feat – a large majority of the "foundational" documents of finance including incorporation documents (that form the foundation of securities markets) and UCC filings (that form the foundation of secured lending) – are filed here. Delaware is home to more than 66% of Fortune 500 companies and 85% of initial public offerings...

Gates Foundation Backs Intarcia Therapeutics’ HIV Drug Pump

Gates Foundation Backs Intarcia Therapeutics’ HIV Drug Pump

The Bill & Melinda Gates Foundation is investing as much as $140 million to support development of a tiny implantable drug pump it believes could help prevent people in sub-Saharan Africa and elsewhere from becoming infected with HIV, the virus that causes AIDS. The matchstick-size pump is being developed by Intarcia Therapeutics Inc., a closely held Boston biotechnology company. It can hold six or 12 months’ supply of medicine and is designed to deliver microdoses continuously to patients, ensuring they stay on the treatment. The new investment, which Intarcia announced Thursday, comes amid a flurry of...

Intarcia Secures 2nd Major Equity Close and Partners with Gates Foundation

Intarcia Therapeutics, Inc., today announced it has completed its second major close of the Series EE equity financing, and also entered into a relationship with the Bill & Melinda Gates Foundation to help prevent the spread of HIV in Sub-Saharan Africa and other countries where the HIV epidemic is most severe. “Thanks to tremendous financing progress, an even stronger shareholder base, our recent NDA submission in type 2 diabetes, and now a groundbreaking relationship with the Bill & Melinda Gates Foundation, Intarcia is poised to open up a totally new category of important once- or twice-yearly treatment and prevention therapies for some of the world’s most serious chronic diseases − including those that disproportionately affect people with some of the greatest unmet needs,” said Kurt Graves, Chairman, President and CEO of Intarcia Therapeutics, Inc...

Citizens Bank Next To Take The Leap With Alt-Lender Fundation

Traditional banks are beginning to embrace their alternative lending competitors as a way to reach more borrowers and get a jumpstart on the technology and digitization behind the lending industry. The latest bank to take part is Citizens Bank, which announced Tuesday (Dec. 20) a partnership with Fundation Group. Fundation has emerged with a reputation to collaborate with banks, not work against them, by offering up its credit solutions and lending technologies to traditional FIs. For Citizens, this means small businesses can apply for...

Kayon Accelerator Comes to Amherst, Mass.

Kayon Partners, in partnership with AmherstWorks, have launched The Kayon Accelerator located in downtown Amherst, Massachusetts.  The new entity will act as a nexus for new businesses and entrepreneurs, combining a range of in-kind services, hands-on help and a co-working location with an expert team focused on positively impacting the trajectory of early-stage businesses. Steve Garrow, Amherst College graduate and Managing Partner of Kayon Partners, added, “The support of the local community has enabled us to...

Intarcia Submits New Drug Application (NDA) to FDA for ITCA 650 in Type 2 Diabetes

Intarcia Therapeutics, Inc. announced it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ITCA 650 for the treatment of type 2 diabetes (T2D). The NDA submission was made in close proximity to World Diabetes Day, and during National Diabetes month in America – two annual events that remind us that type 2 diabetes is one of the largest and fastest-growing public health crises in the world. If approved, ITCA 650 would become the first and only injection-free glucagon-like peptide-1 (GLP-1) receptor agonist therapy. ITCA 650 provides consistent and continuous subcutaneous delivery of exenatide via an osmotic mini-pump placed just under the skin in a simple in office procedure that only takes a healthcare provider a few minutes to perform. ITCA 650 mini-pumps were given with

A New Innovation for Type 2 Diabetes

Indeed, for all the excitement over paradigm-shifting technologies in healthcare and medicine—gene-editing through CRISPR, virtual reality surgical training—it seems we are seeing more and more examples of people solving age-old problems through a stroke of ingenuity. With the proverbial popsicle stick and chewing gum, that is. And sometimes, the two are combined: a bold new technology is coupled with a strikingly simple, intuitive innovation. That has been my initial impression of a new drug-delivery system, called the Medici, which is made by Intarcia Therapeutics. The Medici is...

Delaware Judge Pushes for Blockchain Voting

A Delaware judge has advocated for using blockchain-based voting to put more power in the hands of corporate shareholders. Delaware Chancery Court Vice Chancellor J Travis Laster spoke late last month during a meeting of the Council of Institutional Investors, a non-profit organization dedicated to institutional investment issues. In his speech, Laster took aim at the business ecosystem for proxy voting – services that enable shareholders to cast votes on corporate decisions – arguing that “the current system works poorly and harms stockholders”. But Laster's remarks didn’t come out of nowhere. Earlier this year, the government of Delaware launched an initiative to use the technology as a means to streamline the business registration process in the state. The state government is working with New York-based startup Symbiont on the project...

InkHunter’s AR tattoo app exits beta on Android as startup looks to wider, B2B play

The startup behind a fun, augmented reality tattoo app called InkHunter, covered by TC back in April, is launching its Android app out of beta today — after racking up some 2.5 million downloads on iOS. They’ve been beta testing on Android, as they worked to ensure their AR tech could handle a range of hardware and slower Android devices, but are launching officially now. Their app idea started life as a project cooked up during a 48-hour hackathon back in mid-2014, but the startup is now looking to move beyond being just an app for virtually trying tattoos...

Delaware’s bet on blockchain

First up, the Delaware initiatives will work on using blockchain technology to store contracts and other essential corporate data on a distributed ledger, which will allow companies and agencies to store their documents in more than one location, keep them more secure and automate access by constituents, shareholders and employees. Other benefits include lower costs and longer documents retention, according to Caitlin Long, chairman and president for Symbiont, a technology provider working with the state on “smart contracts. Typically, when documents are stored manually, the document is destroyed once the mandatory retention period passes,” Long said. “This will solve a big problem…